Lessons from fragile X regarding neurobiology, autism, and neurodegeneration

Journal of Developmental and Behavioral Pediatrics

Volumn 27, Issue 1, 2006, Pages 63-74

  Hagerman, Randi J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Fragile X; Neurobiology; Neurodegeneration

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FRAGILE X MENTAL RETARDATION PROTEIN; LITHIUM; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; FMR1 PROTEIN, HUMAN; MESSENGER RNA;

AGITATION; ANXIETY; ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BRAIN ATROPHY; COGNITIVE DEFECT; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; MOOD DISORDER; NERVE DEGENERATION; NEUROBIOLOGY; NEUROPATHY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXICITY; TREMOR; WHITE MATTER; ADULT; ALLELE; ANIMAL; CHILD; DEMYELINATING DISEASE; DISEASE MODEL; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; HETEROZYGOTE DETECTION; MALE; MENTAL DEFICIENCY; NUCLEOTIDE SEQUENCE; PEDIGREE; PSYCHOLOGICAL ASPECT; TRINUCLEOTIDE REPEAT;

ADULT; ALLELES; ANIMALS; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC COUNSELING; GENETIC SCREENING; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HETEROZYGOTE DETECTION; HUMANS; MALE; MENTAL RETARDATION; PEDIGREE; PHENOTYPE; RNA, MESSENGER; TRINUCLEOTIDE REPEATS;

EID: 33646145602     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004703-200602000-00012     Document Type: Review

References (170)

1. Hagerman PJ, Hagerman RJ. Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Ment Retard Dev Disabil Res Rev. 2004;10:25-30.
2. Kenneson A, Zhang F, Hagedorn CH, et al. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet. 2001;10:1449-1454.
3. Maddalena A, Richards CS, McGinniss MJ, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med. 2001;3:200-205.
4. Allingham-Hawkins DJ, Hirji-Babul R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: The international collaborative POF in fragile X study-preliminary data. Am J Med Genet. 1999;83:322-325.
5. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291:460-469.
6. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet. 2000;91:144-152.
7. Jones-Goodlin BL, Tassone F, Gane LW, et al. Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr. 2004;25:392-398.
8. Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations & intermediate alleles. Am J Med Genet. 2003;121B:119-127.
9. Hagerman RJ. Physical and Behavioral Phenotype.In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:3-109.
10. Bennetto L, Pennington BF. Neuropsychology. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment, and Research. 3rd Edition. Baltimore, MD: Johns Hopkins University Press; 2002:206-248.
11. Tassone F, Hagerman RJ, Chamberlain WD, et al. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet. 2000;97:195-203.
12. Turner G, Robinson H, Laing S, et al. Population screening for fragile X. Lancet. 1992;339:1210-1213.
13. Sherman S. Epidemiology. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatmentand Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:136-168.
14. Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMRI gene-and implications for the population genetics of the fragile X syndrome. Am J Hum Genet. 1995;57:1006-1018.
15. Pesso R, Berkenstadt M, Cuckle H, et al. Screening for fragile X syndrome in womenof reproductive age. Prenat Diagn. 2000;20:611-614.
16. Alhadef-Toledano H, Vanagaite-Basel L, Magal N, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet. 2001;69:351-360.
17. Dombrowski C, Levesque S, Morel ML, et al. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11:371-378.
18. Jin P, Warren ST. New insights into fragile X syndrome: from molecules to neurobehaviors. Trends Biochem Sci. 2003;28:52-158.
19. Brown V, Jin P, Ceman S, et al. Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome. Cell. 2001;107:477-487.
20. Miyashiro KY, Mitchener-Beckel A, Purk TP, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in FMR1 null mice. Neuron. 2003;37:417-431.
21. Bardoni B, Mandel JL. Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes. Curr Opin Genet Dev. 2002;12:284-293.
22. Weiler IJ, Spangler CC, Klintsova AY, et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci U S A. 2004;101:17504-17509.
23. Jin P, Zarnescu DC, Ceman S, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004;7:113-117.
24. Siomi H, Ishizuka A, Siomi MC. RNA interference: a new mechanism by which FMRP acts in the normal brain? What can Drosophila teach us? Ment Retard Dev Disabil Res Rev. 2004;10:68-74.
25. Antar LN, Afroz R, Dictenberg JB, et al. Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci. 2004;24:2648-2655.
26. Willemsen R, Oostra BA, Bassell GJ, et al. The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev. 2004;10:60-67.
27. Weiler IJ, Irwin SA, Klintsova AY, et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A. 1997;94:5395-5400.
28. Darnell JC, Warren ST, Darnell RB. The fragile X mental retardation protein, FMRP, recognizes G-quartets. Ment Retard Dev Disabil Res Rev. 2004;10:49-52.
29. O'Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci. 2002;25:315-338.
30. Huber KM, Gallagher SM, Warren ST, et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99:7746-7750.
31. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370-377.
32. Koekkoek SKE, Yamagucki K, Milojkovic BA, et al. Enhanced LTD at enlarged Purkinje cell spines causes motor learning deficits in fragile X syndrome. Neuron. In press.
33. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior and mushroom body defects in a drosophila model of fragile X syndrome. Neuron. 2005;45:753-764.
34. Rogers SJ, Wehner EA, Hagerman RJ. The Behavioral Phenotype in Fragile X: Symptoms of Autism in Very Young Children with Fragile X Syndrome, Idiopathic Autism, and other Developmental Disorders. J Dev Behav Pediatr. 2001;22:409-417.
35. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10:31-41.
36. Tassone F, Hagerman RJ, Ikle DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet. 1999;55:346-351.
37. Abrams MT, Reiss AL, Freund LS, et al. Molecular-neurobehavioral associations in females with the fragile X full mutation. Am J Med Genet. 1994;51:317-327.
38. Loesch DZ, Huggins RM, Bui QM, et al. Effect of the deficits of fragile X mental retardation protein on cognitive status of fragile X males and females assessed by robust pedigree analysis. J Dev Behav Pediatr. 2002;23:416-423.
39. Bailey DB, Hatton DD, Tassone F, et al. Variability in FMRP and early development in males with fragile X syndrome. Am J Ment Retard. 2001;106:16-27.
40. de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Med Genet. 1996;58: 1025-1032.
41. Hagerman RJ, Hull CE, Safanda JF, et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet. 1994;51:298-308.
42. Hatton DD, Hooper SR, Bailey DB, Skinner ML, Sullivan KM, Wheeler A. Problem behavior in boys with fragile X syndrome. Am J Med Genet. 2002;108:105-116.
43. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics. 1993;91:321-329.
44. Hagerman RJ, Hills J, Scharfenaker S, et al. Fragile X Syndrome and Selective Mutism. Am J Med Genet. 1999;83:313-317.
45. Merenstein SA, Shyu V, Sobesky WE, et al. Fragile X syndrome in a normal IQ male with learning and emotional problems. J Am Acad Child Adolesc Psychiatry. 1994;33:1316-1321.
46. Loesch D, Huggins R, Bui QM, et al. Effect of the fragile X status categories and FMRP deficits on cognitive profiles estimated by robust pedigree analysis. Am J Med Genet. 2003;122A:12-23.
47. Beilina A, Tassone F, Schwartz PH, Sahota P, Hagerman PJ. Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element. Hum Mol Genet. 2004;13:543-549.
48. Primerano B, Tassone F, Hagerman RJ, et al. Reduced FMR1 mRNA translation efficiency in Fragile X patients with premutations. RNA. 2002;8:1482-1488.
49. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in fragile X syndrome. Am J Hum Genet. 2000;66:6-15.
50. Loesch DZ, Hay DA, Mulley J. Transmitting males and carrier females in fragile X-revisited. Am J Med Genet. 1994;51:392-399.
51. Loesch DZ, Huggins RM, Bui QM, et al. Relationship of deficits of FMR1 gene specific protein with physical phenotype of fragile X males and females in pedigrees: A new perspective. Am J Med Genet. 2003;118A:127-134.
52. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association; 1994.
53. Gillberg C. Chromosomal disorders and autism. J Autism Dev Disord. 1998;28:415-425.
54. Chudley AE, Gutierrez E, Jocelyn LJ, et al. Outcomes of genetic evaluation in children with pervasive developmental disorder. J Dev Behav Pediatr. 1998;19:321-325.
55. Reddy KS. Cytogenetic abnormalities and fragile-X syndrome in Autism Spectrum Disorder. BMC Med Genet. 2005;6:3.
56. Estecio M, Conte-Fett AC, Garcia-Varella M, et al. Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders. J Autism Dev Disord. 2002;32:35-41.
57. Brown WT, Jenkins EC, Cohen IL, et al. Fragile X and autism: a multicenter survey. Am J Med Genet. 1986;23:341-352.
58. Wassink TH, Piven J, Patil SR. Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. Psychiatr Genet. 2001;11:57-63.
59. Li SY, Chen YC, Lai TJ, et al. Molecular and cytogenetic analyses of autism in Taiwan. Hum Genet. 1993;92:441-445.
60. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205-223.
61. Le Couteur A, Rutter M, Lord C, et al. Autism Diagnostic Interview: A standardized investigator-based instrument. J Autism Dev Disord. 1989;19:363-387.
62. BrownWT, Jenkins EC, Friedman E, et al. Autism is associated with the fragile-X syndrome. J Autism Dev Disord. 1982;12:303-308.
63. Hagerman RJ, Jackson AW, Levitas A, et al. An analysis of autism in fifty males with the fragile X syndrome. Am J Med Genet. 1986;23:359-374.
64. Reiss AL, Freund L. Fragile X syndrome, DSM-III-R, and autism. J Am Acad Child Adolesc Psychiatry. 1990;29:885-891.
65. Bailey DB, Mesibov GB, Hatton DD, et al. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord. 1998;28:499-508.
66. Cohen IL, Sudhalter V, Pfadt A, et al. Why are autism and the fragile-X syndrome associated? Conceptual and methodological issues. Am J Hum Genet. 1991;48:195-202.
67. Schopler E, Reichler RJ, De Vellis RF, et al. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord. 1980;10:91-103.
68. Kau AS, Tiemey E, Bukelis I, et al. Social behavior profile in young males with fragile X syndrome: Characteristics and specificity. Am J Med Genet. 2004;126A:9-17.
69. Philofsky A, Hepburn SL, Hayes A, et al. Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome. Am J Ment Retard. 2004;109:208-218.
70. Kaufmann WE, Cortell R, Kau AS, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet. 2004;129A:225-234.
71. Bailey DB, Hatton DD, Mesibov G, et al. Early development, temperament and functional impairment in autism and fragile X syndrome. J Autism Dev Disord. 2000;30:49-59.
72. Hatton DD, Wheeler AC, Skinner ML, et al. Adaptive behavior in children with fragile X syndrome. Am J Ment Retard. 2003;108:373-390.
73. Demark JL, Feldman MA, Holden JJA. Behavioral relationship between autism and fragile X syndrome. Am J Ment Retard. 2003;108:314-326.
74. Loesch DZ, Bui MQ, Grigsby J, et al. Effect of the fragile X status categories and the FMRP levels on executive functioning in fragile X males and females. Neuropsychology. 2003;17:646-657.
75. Bailey DB, Hatton DD, Skinner M, et al. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. J Autism Dev Disord. 2001;31:165-174.
76. Harris SW, Jones-Goodlin B., Nowicki S, et al. ADOS-G profiles in males with fragile X syndrome. Paper presented at: 54th Annual Meeting of the American Society of Human Genetics; October 26-30, 2004; Toronto, ON.
77. Nowicki ST, Li L, Milliken DB, et al. Genes epistatic to FMR1 involved in the autism behavioral phenotype. Paper presented at: 54th Annual Meeting of the American Society of Human Genetics; October 26-30, 2004; Toronto, ON.
78. Glaser B, Hessl D, Friedman-Dye J, et al. Biological and environmental contributions to adaptive behavior in fragile X syndrome. Am J Med Genet A. 2003;117:21-29.
79. Hessl D, Friedman-Dyer J, Glaser B, et al . The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001;108:e88.
80. Friedman-Dyer J, Glaser B, Hessl D, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41:237-244.
81. de Vries BB, Fryns JP, Butler MG, et al. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet. 1993;30:761-766.
82. Stumple-Schrander C, Gerver WJ, Meyer H, et al. Prader-Willilike phenotype in fragile X syndrome. Clin Genet. 1994;45:175-180.
83. Stalker HJ, Keller KL, Gray BA, et al. Concurrence of fragile X syndrome and 47, XYY in an individual with a Prader-Willi-like phenotype. Am J Med Genet A. 2003;116:176-178.
84. Stoll C. Problems in the diagnosis of fragile X syndrome in young children are still present. Am J Med Genet. 2001;100:110-115.
85. deVries BB, Niermeijer MF. The Prader-Willi-like phenotype in fragile X patients: a designation facilitating clinical (and molecular) differential diagnosis. J Med Genet. 1994;31:820.
86. Gillessen-Kaesbach G, Horsthemke B. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet. 1994;31:260-261.
87. Schenck A, Bardoni B, Langmann C, et al. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron. 2003;38:887-898.
88. Chai JH, Locke DP, Greally JM, et al. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet. 2003;73:898-925.
89. Butler MG, Brunschwig A, Miller LK, et al. Standards for selected anthropometric measurements in males with the fragile X syndrome. Pediatrics. 1992;89:1059-1062.
90. Shapiro M, Murphy G, Hagerman RJ, et al. Adult fragile X syndrome: Neuropsychology; brain anatomy and metabolism. Am J Med Genet. 1995;60:480-493.
91. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003;290:337-344.
92. Chiu S, Hessl D, Day J, et al. Genetic Correlates of Psychiatric Comorbidity in Fragile X Syndrome. In Bax M, ed. Comorbidities in Genetic Syndromes. London, England: MacKeith Press; in press.
93. Reiss AL, Freund L, Tseng JE, et al. Neuroanatomy in fragile X females: the posterior fossa. Am J Hum Genet. 1991;49:279-288.
94. Reiss AL, Aylward E, Freund LS, et al. Neuroanatomy of fragile X syndrome: the posterior fossa. Ann Neurol. 1991;29:26-32.
95. Mostofsky SH, Mazzocco MM, Aakalu G, et al. Decreased cerebellar posterior vermis size in fragile X syndrome. Am Acad Neurol. 1998;50:121-130.
96. Courchesne E, Saitoh O, Courchesne-Yeung R, et al. Abnormality of cerebellar vermian lobules VI and VII in patients with infantile autism: identification of hypoplastic and hyperplastic subgroups with MR imaging. Am J Roentgenol. 1994;162:123-130.
97. Kaufmann WE, Cooper KL, Mostofsky SH, et al. Specificity of cerebellar vermian abnormalitiesin autism: a quantitative magnetic resonance imaging study. J Child Neurol. 2003;18:463-470.
98. Bauman ML. Microscopic neuroanatomic abnormalities in autism. Pediatrics. 1991;87:791-796.
99. Sabaratnam M. Pathological and neuropathological findings in two males with fragile X syndrome. J Intellect Disabil Res. 2000;44:81-85.
100. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57:1618-1628.
101. Goraly-Barnea N, Eliez S, Hedeus M, et al. White matter tract alterations in fragile X syndrome: preliminary evidence from diffusion tensor imaging. Am J Med Genet. 2003;118B:81-88.
102. Just MA, Cherkassky VL, Keller TA, et al. Cortical activation and synchronization during sentence comprehension in high-functioning autism: evidence of underconnectivity. Brain. 2004;127:1811-1821.
103. Herbert MR, Ziegler DA, Makris N, et al. Localization of white matter volume increase in autism and developmental language disorder. Ann Neurol. 2004;55:530-540.
104. Rivera SM, Menon V, White CD, et al. Functional Brain Activation During Arithmetic Processing in Females with fragile X Syndrome is Related to FMR1 Protein Expression. Hum Brain Mapp. 2002;16:206-218.
105. Menon V, Mackenzie K, Rivera SM, et al. Prefrontal cortex involvement in processing incorrect arithmetic equations: evidence from event-related fMRI. Hum Brain Mapp. 2002;16:119-130.
106. Menon V, Leroux J, White CD, et al. Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci U S A. 2004;101:3615-3620.
107. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex. 2000;10:1038-1044.
108. Miller LJ, McIntosh DN, McGrath J, et al. Electrodermal Responses to Sensory Stimuli in Individuals with Fragile X Syndrome: A Preliminary Report. Am J Med Genet. 1999;83: 268-279.
109. Roberts JE, Boccia ML, Bailey DB, et al. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. Dev Psychobiol. 2001;39:107-123.
110. Frankland PW, Wang Y, Rosner B, et al. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry. 2004;9:417-425.
111. McAlonan GM, Daly E, Kumari V, et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain. 2002;125:1594-1606.
112. Hagerman RJ, Staley LW, O'Connor R, et al. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics. 1996;97:122-126.
113. Sobesky WE, Porter D, Pennington BF, et al. Dimensions of shyness in fragile X females. Developmental Brain Dysfunction. 1995;8: 280-292.
114. Sobesky WE, Taylor AK, Pennington BF, et al. Molecular-clinical correlations in females with fragile X. Am J Med Genet. 1996;64:340-345.
115. Franke P, Leboyer M, Gansicke M, et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res. 1998;80:113-127.
116. Reiss AL, Freund L, Abrams MT, et al. Neurobehavioral effects of the fragile X premutation in adult women: a controlled study. Am J Hum Genet. 1993;52:884-894.
117. Bennetto L, Pennington BF, Taylor A, et al. Profile of cognitive functioning in women with the fragile X mutation. Neuropsychology. 2001;15:290-299.
118. Johnston C, Eliez S, Friedman-Dyer J, et al. Neurobehavioral phenotype in carriers of the fragile X premutation. Am J Med Genet. 2001;103:314-319.
119. Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10:17-24.
120. Lachiewicz AM. Abnormal behaviors of young girls with fragile X syndrome. Am J Med Genet. 1992;43:72-77.
121. Cronister A, Schreiner R, Wittenberger M, et al. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet. 1991;38:269-274.
122. Schwartz CE, Dean J, Peebles-Howard PN, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet. 1994;51:400-402.
123. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57:127-130.
124. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging Correlates. Am J Hum Genet. 2003;72:869-878.
125. Bacalman S, Farzin F, Bourgeois J, et al. Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males: Newly Described Fronto-Subcortical Dementia. J Clin Psychiatry. 2006;67:87-94.
126. LeeheyMA, Munhoz RP, Lang AE, et al. The Fragile X Premutation Presenting as Essential Tremor. Arch Neurol. 2003;60:117-121.
127. Leehey M, Hagerman RJ, Landau WM, et al. Tremor/Ataxia syndrome in fragile X carrier males. Mov Disord. 2002;17:744-745.
128. Kravis-Berry E, Lewin F, Wuu J, et al. Tremor and Ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol. 2003;53:616-623.
129. Cornish KM, Kogan C, Turk J, et al. The emerging fragile X premutation phenotype: Evidence from the domain of social cognition. Brain Cogn. 2005;57:53-60.
130. Hessl D, Tassone F, Loesch D, et al. Abnormal elevation of FMR1 mRNA is associated with psychopathology in adults with the fragile X premutation. Am J Med Genet: Neuropsychiatr Genet. 2005;138:115-121.
131. Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: Characteristic MR imaging findings in adult males with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol. 2002;23:1757-1766.
132. Greco C, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain. 2002;125:1760-1771.
133. Iwahashi CK, Yasui DH, An H-J, et al. Neural cell intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain. 2006;129:256-271.
134. Hall DA, Kravis-Berry E, Jacquemont S, et al. Prior Diagnoses Given to Persons with the Fragile X Associated Tremor/Ataxia Syndrome (FXTAS). Neurol. 2005;65:299-301.
135. Macpherson J, Waghorn A, Hammans S, et al. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet. 2003;112:619-620.
136. Van Esch H, Dom R, Bex D, et al. Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet. 2005;13:121-123.
137. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004;74:805-816.
138. Ranum LP, Day JW. Dominantly inherited, non-coding microsatellite expansion disorders. Curr Opin Genet Dev. 2002;12:266-271.
139. Willemsen R, Westerveld-Hoogeveen M, Reis S, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet. 2003;12:949-959.
140. Jin P, Zarnescu DC, Zhang F, et al. RNA-Mediated Neurodegeneration Caused by the Fragile X Premutation rCGG Repeats in Drosophila. Neuron. 2003;39:739-747.
141. Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004;74:1051-1056.
142. Zuhlke C, Budnik A, Gehlken U, et al. FMR1 premutation as a rare cause of late onset ataxia-evidence for FXTAS in female carriers. J Neurol. 2004;251:1418-1419.
143. Kravis-Berry E, Potanos K, Weinberg D, et al. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol. 2005;57:144-147.
144. Jacquemont S, Orrico A, Galli L, et al. Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS? J Med Genet. 2005;42:e14.
145. Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab. 2004;89:4569-4574.
146. Jacquemont S, Farzin F, Hall D, et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard. 2004;109:154-164.
147. Mothersead PK, Conrad K, Hagerman RJ, et al. An Atypical Progressive Dementia in a Male Carrier of the Fragile X Premutation: An Example of Fragile X-Associated Tremor/Ataxia Syndrome. Appl Neuropsychol. 2005;12:169-179.
148. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev. 2004;10:42-48.
149. Hagerman RJ. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:287-338.
150. Scharfenaker S, O'Connor R, Stackhouse T, et al. An integrated approach to intervention. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:363-427.
151. Epstein J, Riley K, Sobesky W. The treatment of emotional and behavioral problems. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment, and Research. Baltimore, MD: The Johns Hopkins University Press; 2002:339-362.
152. Braden M. Academic interventions in Fragile X. In: Hagerman RJ, Hagerman PJ eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:428-464.
153. Braden M. Fragile, Handle with Care: More about Fragile X Syndrome, Adolescents and Adults. Dillon: Spectra Publishing Co; 2000.
154. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30:377-392.
155. Hagerman RJ, Miller LJ, Clarke-McGrath J, et al. Influence of Stimulants on Electrodermal Studies in Fragile X Syndrome. Microsc Res Tech. 2002;57:168-173.
156. Amaria RN, Billeisen LL, Hagerman RJ. Medication Use in Fragile X Syndrome. Ment Health Aspects Dev Disabil. 2001;4:143-147.
157. Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. in press.
158. Bauchwitz RP. What elevated audiogenic seizure susceptibility in fragile-X mice reveals about the etiology of fragile-X syndrome. Paper presented at: New Pharmacological and Neurobiological Approaches to the Treatment of Fragile-X; April 25-28, 2004; Cold Spring Harbor Laboratory, New York.
159. Berridge MJ. The Albert Lasker Medical Awards. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA. 1989;262:1834-1841.
160. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361:315-325.
161. Takei K, Shin RM, Inoue T, et al. Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Science. 1998;282:1705-1708.
162. Larsen GA, Johnsen-Berg J, Moe MC, et al. Calcium-dependent protein kinase C activation in acutely isolated neurons during oxygen and glucose deprivation. Neurochem Res. 2004;29:1931-1937.
163. Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306:882-884.
164. Cornish K, Sudhalter V, Turk J. Attention and Language in Fragile X. Ment Retard Dev Disab Res Rev. 2004;10:11-16.
165. Cornish KM, Turk J, Wilding J, et al. Annotation: Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach. J Child Psychol Psychiatry. 2004;45:1042-1053.
166. Hagerman RJ. Medical Follow-up and Pharmacotherapy. In: Hagerman RJ, Cronister A, eds. Fragile X Syndrome: Diagnosis, Treatment, and Research. 2nd edition. Baltimore, MD: The Johns Hopkins University Press; 1996:283-331.
167. Gane L, Cronister A. Genetic Counseling. In: Hagerman RJ, Hagerman PJ, eds. Fragile X Syndrome: Diagnosis, Treatment, and Research. 3rd edition. Baltimore, MD: The Johns Hopkins University Press; 2002:251-286.
168. Hagerman PJ, Hagerman RJ, Gane L. Genetic counseling for families of patients with fragile X syndrome. JAMA. 2004;291:2945-2946.
169. Dolen G, Bear MF. Courting a cure for fragile X. Neuron. 2005;45:642-644.
170. Bailey DB. Newborn screening for fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10:3-10.